ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of Compound xiongshao capsules in the treatment of diabetic peripheral neuropathy (DPN).METHODS:A total of 97 DPN patients selected from our hospital during Jun.2015-Apr.2016 were divided into group A (compound xiongshao treatment group,46 cases) and control group (51 cases) according to random number table.The latter was divided into group B (epalrestat+beraprost sodium group,12 cases),group C (fursultiamine+mecobalamin group,12 cases) and group D (epalrestat group,27 cases) according to clinical symptoms and economic situation of patients.Four groups were given antidiabetic drugs for blood glucose control.Based on it,group A was additionally given Compound xiongshao capsules 0.9 g,tid;group B was additionally given Epalrestat tablets 50 mg,tid+Beraprost sodium tablets 40 μg,tid;group C was additionally given Fursultiamine tablets 50 mg,tid+Mecobalamin tablets 0.5 mg,rid;group D was additionally given Epalrestat tablets 50 mg,tid.All groups were treated for 6 months.Clinical efficacies were observed.TCSS scores,motor nerve conduction velocity (MCV),sensory nerve conduction velocity (SCV),incubation period and amplitude of median nerve and common peroneal nerve,the levels of hemorheology indexes,blood glucose,glycosylated hemoglobin,blood lipid,serum creatinine were compared before and after treatment.The occurrence of ADR was recorded.RESULTS:Total response rates of group A and B (82.61％,83.33％)were significantly higher than those of group C and D (33.33％,66.67％),total response rate of group D was significantly higher than that of group C,with statistical significance (P＜0.05).Before treatment,there was no statistical significance in TCSS scores,MCV,SCV,incubation period and amplitude of median nerve,MCV and amplitude of common peroneal never,SCV,incubation period and amplitude of common peroneal never or whole blood high-shear viscosity among 4 groups (P＞0.05).After treatment,TCSS scores of group A,B and D were decreased significantly compared to before treatment,and those of group A and B were lower than those of group C and D,with statistical significance (P＜0.05).MCV,incubation period and amplitude of median nerve in group A and B,amplitude of median nerve in group C,MCV and amplitude of median nerve in group D were significantly better than before treatment;MCV,incubation period and amplitude of median nerve in group A and B were significantly better than group C and D,with statistical significance (P＜0.05).MCV,incubation period and amplitude of common peroneal never in group A,B,C were significantly better than before treatment,MCV and amplitude of common peroneal never in group A,B were significantly better than group C,D;the improvement of incubation period of common peroneal never in group A,B,D were significantly better than group C,with statistical significance (P＜0.05).SCV,incubation period and amplitude of median nerve,SCV and amplitude of common peroneal nerve in group A,B and D were significantly better than before treatment;SCV,incubation period and amplitude of median nerve,SCV and amplitude of common peroneal nerve in group A,SCV,incubation period and amplitude of median nerve and amplitude of common peroneal nerve in group B were significantly better than group C and D;SCV of median nerve in group D was significantly better than group C,with statistical significance (P＜0.05).Whole blood high-shear viscosity of group A was decreased significantly compared to before treatment,and significantly lower than those of group B,C and D,with statistical significance (P＜0.05).There was no statistical significance in total response rate and TCSS score between group A and B,and in the levels of blood glucose,glycosylated hemoglobin,blood lipid or serum creatinine among 4 groups (P＞0.05).No obvious ADR was found in 4 groups.CONCLUSIONS:Compound xiongshao capsules shows significant therapeutic efficacy for DPN,and improves nerve conduction velocity,incubation period and amplitude of median nerve and common peroneal nerve,whole blood high-shear viscosity.Its effect is similar to that of epalrestat combined with beraprost sodium,and better than those of fursultiamine combined with mecobalamin,epalrestat alone.It does not affect the blood glucose,blood lipid and serum creatinine levels with good safety.
ABSTRACT
Objective To explore the efficacy ofTiaogan-Bushen-Xiaoji recipe (TGBSXJ Recipe) on overall survival and progression free survival (PFS) in patients with advanced breast cancer.Methods A total of 105 patients with advanced breast cancer, who received the first-line treatment, were divided into two groups, 56 cases in the control group and 49 in the experimental group. The control group received standard therapy according to guidelines, including chemotherapy, targeted therapy, endocrine therapy and treatment of bisphosphonates.The experimental group received the treatment of TGBSXJ Recipe besides the standard therapy. The overall survival (OS), progression-free survival (PFS) and Karnofsky (KPS) of the patients in two groups were observed and compared. The treatment ended with the sighs of the observation ending, the second progress for the disease or death.Results The overall survival of the experimental group was significantly higher than that of the control group [OS: 58.2(50.7-65.8)/monthsvs. 43.8(30.6-51.6)/months,P=0.040]. The PFS of the experimental group was significantly higher than the control group [PFS: 30.7(23.8-37.7)/monthsvs. 15.2(11.3-19.1)/months,P=0.001]. The KPS of the experimental group was significantly higher than the control group (88.6 ± 10.0vs. 80.5 ± 19.0,t=2.654). The PFS of the triple negative breast cancer (TNBC) in the experimental group was significantly higher than control group [(25.1(12.1-38.0)/monthsvs. 9.9(4.7-15.0)/months,P=0.038].Conclusions The TGBSXJ recipe could extend the OS and PFS and improve the life quality of the patients with advanced breast cancer. In this study, no severe adverse effects had been found in the experimental group.
ABSTRACT
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted treatment has been a standard therapy for advanced non-small cell lung cancer (NSCLC), but it is not tolerated well by all patients. In China, some studies have reported that traditional Chinese medicinal herbs (TCMHs) may increase efficacy and reduce toxicity when combined with EGFR-TKI, but outside of China few studies of this kind have been attempted.
ABSTRACT
OBJECTIVE: To observe the clinical therapeutic effects of Dishen Qufeng Decoction (DSQFD), a compound traditional Chinese herbal medicine, in treatment of allergic rhinitis. METHODS: Sixty cases of allergic rhinitis were selected and randomized into DSQFD group (30 cases) and cetirizine group (30 cases), and the patients were orally administered DSQFD and cetirizine respectively. The integrals of patients' symptoms, such as sneezing, nose running, nasal occlusion and nasal itching, signs in the nasal conchae and peripheral blood eosinophil (EOS) count were abserved count before and after treatment. RESULTS: DSQFD obviously improved the symptoms and signs of allergic rhinitis. The total response rate of DSQFD treatment was 83.3%, while that of the cetirizine treatment was 86.7%; the EOS counts in both groups were significantly decreased. These results showed statistical difference between the two groups. CONCLUSION: DSQFD is an effective preparation of traditional Chinese medicine for treating allergic rhinitis.
ABSTRACT
To study the effects of intraperitoneal chemotherapy (IPC) plus Shenmai Injection (SMI) in treating advanced colorectal cancer following radical resections.
ABSTRACT
Purpose:To study the analgesic role of Shikangning(SKN) injection (containing scorpion venom protein) on cancer pain. Methods:In the clinical trial, controls were used(41 cases,who were divided into two groups by the use of randomized double blind methed: SKN group 21 cases and placebo group 20 cases) and the open test (total of 88 cases, 67cases were given drug for 7 days, and 21 cases, for 14 days). Results:In the controlled trial, pain intensity difference(PID) and sum pain intensity difference(SPID) level of SKN group were higher than those in the placebo group ( P
ABSTRACT
Objective: To prove the clinical therapeutic effect of acute and chronic bronchial asthma with Chuankezhi(CKZ) Injection. Methods: 40 cases of bronchial asthma, including inpatients and outpatients were selected, divided into the attack period group (20) and the relief period group (20). The former was intramuscularly injected CKZ injection 4mL, twice a day, 14 days being a course of treatment. The latter was intramuscularly injected CKZ injection 4mL, twice a day for 15～30 days and 2mL, every other day for 31～90 days; 90 days being a course of treatment. The symptoms and signs, such as asthma, cough, expectroation, pulmonary wheeze were observed. and pulmonary function, absolute eosinophilic granulocyte count and immunogobulin E were measured before and after treatment. Result: By the use of CKZ injection to treat bronchial asthma, the total effective rate amounted to 85% and obvious difference before and after treatment in the two groups ( P
ABSTRACT
AIM: To study the clinical efficacy of Jinchang Capsule for the treatment of type 2 diabetes of blood-stasis syndrome. METHODS: From JAN.2001 to OCT.2004, 48 cases were divided randomly into two groups.32 cases in the treatment group were treated with oral Jinchang Capsule combined with Western medicine therapy, and 22 cases in the control group were simply treated with Western medicine therapy, with a course of 8 weeks. The changes of clinical symptoms, and fasting blood glucose (FBG), 2 h post prandial glucose(2hFBG), HbAlc, total cholesterol (Tc), triglycerides (TG), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c) levels, and hemorheological parameters were analysed. The safety of the medicine was evaluated also. RESULTS: After treatment, the clinical symptomatic integrals were decreased remarkably in the treatment group (P0.05). There was no significant side-effect in the treatment group. CONCLUSION: The results obtained suggest that Jinchang Capsule can improve the clinical symptomatic integrals and remarkably enhance total clinical efficacy. Combining with the basic Western medicinal treatment of diabetes, it can control the obstinate hyperglycemia, and improve fat metabolism as well as bemorheological parameters. It has indicated that Jinchang Capsule has multipurpose therapeutic actions for diabetes mellitus.